Multiple Myeloma: all 3,712 studies

Page 13 of 38. Open to participants first (752), then studies with results posted, then the rest; newest registration first within each.

• A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)CompletedNCT01602224Phase 2Results posted
• An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple MyelomaCompletedNCT01592370Phase 1/2Results posted
• Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine ConditioningCompletedNCT01572662Phase 2Results posted
• Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple MyelomaCompletedNCT01572480Phase 2Results posted
• Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma PatientsCompletedNCT01568866Phase 3Results posted
• A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple MyelomaCompletedNCT01564537Phase 3Results posted
• Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple MyelomaCompletedNCT01559935Phase 2Results posted
• Study of Tabalumab (LY2127399) in Japanese Participants With Relapsed or Refactory Multiple MyelomaCompletedNCT01556438Phase 1Results posted
• Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior TreatmentTerminatedNCT01548573Phase 2Results posted
• Collection of Transplant Stem Cells for Plasma Cell MyelomaCompletedNCT01547806Phase 2Results posted
• 1068GCC Evaluate Efficacy & Explore Mechanism of Acupuncture in Treating Bortezomib-induced Peripheral Neuropathy (BIPN) in Multiple MyelomaCompletedNCT01541644Not applicableResults posted
• Velcade (Bortezomib) Consolidation After TransplantCompletedNCT01539083Phase 3Results posted
• CP-751,871 Treatment For Patients With Multiple MyelomaCompletedNCT01536145Phase 1Results posted
• High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma Undergoing Stem Cell TransplantTerminatedNCT01534143Phase 2Results posted
• Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM)CompletedNCT01531998Phase 1/2Results posted
• Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic MalignanciesCompletedNCT01529827Phase 2Results posted
• Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological MalignanciesCompletedNCT01527045Phase 2Results posted
• A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive CancersCompletedNCT01524978Phase 2Results posted
• Vorinostat,Lenalinomide and Dexamethasone in Multiple Myeloma Refractory to Previous Lenalinomide Containing RegimensCompletedNCT01502085Phase 1/2Results posted
• Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic MalignanciesCompletedNCT01499147Not applicableResults posted
• Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple MyelomaCompletedNCT01496118Phase 1/2Results posted
• Bendamustine, Wkly Bortezomib, Lenalidomide and Dexamethasone for Multiple MyelomaTerminatedNCT01484626Phase 1/2Results posted
• Eltrombopag for Thrombocytopenia in Patients With Relapsed Multiple MyelomaTerminatedNCT01484314Phase 2Results posted
• A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple MyelomaCompletedNCT01484275Phase 2Results posted
• Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple MyelomaCompletedNCT01478581Phase 2Results posted
• Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple MyelomaCompletedNCT01478048Phase 2Results posted
• Lenalidomide Intensification in Patients With Serologic/Asymptomatic Progression of Multiple Myeloma While on Lenalidomide MaintenanceCompletedNCT01463670Phase 2Results posted
• Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating FactorCompletedNCT01459653Results posted
• A Study to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 Alone or in Combination With G-CSF in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin DiseaseCompletedNCT01458288Phase 2Results posted
• A Study of DKN-01 in Multiple Myeloma or Advanced Solid TumorsCompletedNCT01457417Phase 1Results posted
• Allogeneic Hematopoietic Stem Cell Transplantation for Multiple MyelomaCompletedNCT01453101Phase 2Results posted
• Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or OlderTerminatedNCT01453088Phase 2Results posted
• Study of Hyperbaric Oxygen Therapy in Addition to Standard Growth Factor Support for Hematopoietic Progenitor/Stem Cell MobilizationTerminatedNCT01449539Not applicableResults posted
• Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple MyelomaCompletedNCT01447914Phase 2Results posted
• Biomarker Study of Elotuzumab in High Risk Smoldering MyelomaCompletedNCT01441973Phase 2Results posted
• Chloroquine in Combination With VELCADE and Cyclophosphamide for Relapsed and Refractory Multiple MyelomaTerminatedNCT01438177Phase 2Results posted
• Pomalidomide in Combination With High Dose Dexamethasone and Oral CyclophosphamideCompletedNCT01432600Phase 1/2Results posted
• Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological MalignanciesCompletedNCT01427881Phase 2Results posted
• Id-KLH Vaccine + T Cells in Subjects With Myeloma Undergoing TransplantCompletedNCT01426828Phase 2Results posted
• Common Safety Follow-up Trial of Tecemotide (L-BLP25)TerminatedNCT01423760Not applicableResults posted
• A Phase 1/2a Study of Human Anti-CD 38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple MyelomaCompletedNCT01421186Phase 1/2Results posted
• Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to BortezomibCompletedNCT01415882Phase 2Results posted
• A Randomized Trial to Compare Busulfan + Melphalan 140 mg/m2 With Melphalan 200 mg/m2 as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple MyelomaCompletedNCT01413178Phase 3Results posted
• Reduced Intensity Double Umbilical Cord Blood TransplantationCompletedNCT01408563Phase 2Results posted
• Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma PatientsCompletedNCT01402284Phase 2Results posted
• Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal FunctionCompletedNCT01393964Phase 1Results posted
• A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological MalignanciesCompletedNCT01384513Phase 2Results posted
• Study of Oral IXAZOMIB in Combination With Lenalidomide and Dexamethasone in Participants With Newly Diagnosed Multiple MyelomaCompletedNCT01383928Phase 1/2Results posted
• Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL AmyloidosisCompletedNCT01383759Not applicableResults posted
• MAGE-A3 Protein + AS15 as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell TransplantationCompletedNCT01380145Phase 1Results posted
• Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple MyelomaCompletedNCT01380106Phase 2Results posted
• Administration of Tadalafil in Conjunction With Lenalidomide and Dexamethasone in Patients With Multiple MyelomaTerminatedNCT01374217Phase 2Results posted
• Phase 1-2 Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple MyelomaCompletedNCT01355705Phase 1/2Results posted
• Redirected Auto T Cells for Advanced MyelomaCompletedNCT01352286Phase 2Results posted
• Infusional Carfilzomib in Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT01351623Phase 2Results posted
• Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative DonorCompletedNCT01350245Phase 2Results posted
• Allogeneic GM-CSF Vaccine and Lenalidomide in Treating Myeloma Patients With Near Complete RemissionCompletedNCT01349569Phase 2Results posted
• Delanzomib (CEP-18770) in Combination With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple MyelomaCompletedNCT01348919Phase 1/2Results posted
• Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple MyelomaCompletedNCT01345019Phase 3Results posted
• Phase I Study of OPB-51602 in Patients With Hematologic MalignanciesCompletedNCT01344876Phase 1Results posted
• Preservation of Ovarian Function After Hematopoietic Cell TransplantTerminatedNCT01343368Phase 2Results posted
• Study of Oral Ixazomib in Combination With Melphalan and Prednisone in Participants With Newly Diagnosed Multiple MyelomaCompletedNCT01335685Phase 1/2Results posted
• Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple MyelomaCompletedNCT01335399Phase 3Results posted
• Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid TumorsCompletedNCT01326702Phase 1/2Results posted
• Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple MyelomaCompletedNCT01324947Phase 3Results posted
• Continuous Versus Intermittent Dosing Regimens for Pomalidomide in Relapsed/Refractory Multiple MyelomaCompletedNCT01319422Phase 2Results posted
• Bortezomib and Bendamustine to Treat Relapsed/Refractory MyelomaTerminatedNCT01315873Phase 2Results posted
• A Study of Bone Marrow Transplantation Using Fully-Matched Relatives as Donors for Patients With Hematological MalignanciesCompletedNCT01315132Phase 2Results posted
• Efficacy of Gamma Camera Used Intraoperatively for ID of Sentinel Lymph Nodes w/ LymphoscintigraphyCompletedNCT01314963Not applicableResults posted
• UARK 2010-35, A Study of Expanded Natural Killer Cell Therapy for Multiple MyelomaCompletedNCT01313897Phase 2Results posted
• A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion StudyCompletedNCT01311687Phase 3Results posted
• Allo Transplant Followed by Lenalidomide and Sirolimus Maintenance in High-Risk Multiple Myeloma (MM)TerminatedNCT01303965Phase 1/2Results posted
• A Study of Carfilzomib vs Best Supportive Care in Subjects With Relapsed and Refractory Multiple MyelomaCompletedNCT01302392Phase 3Results posted
• A Trial of TBL12 Sea Cucumber Extract in Patients With Untreated Asymptomatic MyelomaTerminatedNCT01302366Phase 2Results posted
• Filgrastim With or Without Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With LenalidomideTerminatedNCT01301963Phase 3Results posted
• Evaluation of the Spectra Optia® Mononuclear Cell Collection ProcedureCompletedNCT01292486Not applicableResults posted
• Velcade Consolidation Bone StudyCompletedNCT01286077Phase 2Results posted
• Prevention of Treatment Induced Neuropathy in Multiple MyelomaCompletedNCT01283997Phase 2Results posted
• Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic MalignanciesCompletedNCT01273766Phase 2Results posted
• Dose Escalation Trial of Denileukin Diftitox (Ontak) Post Autologous TransplantationTerminatedNCT01251952Phase 1Results posted
• Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell TransplantCompletedNCT01251575Phase 2Results posted
• A Phase II Trial of Anti-KIR in Smoldering Multiple MyelomaTerminatedNCT01248455Phase 2Results posted
• Carfilzomib, Pegylated Liposomal Doxorubicin Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT01246063Phase 1/2Results posted
• Combination Immunotherapy and Autologous Stem Cell Transplantation for MyelomaCompletedNCT01245673Phase 2Results posted
• Escalating Doses of Thalidomide in Conjunction With Bortezomib and HIgh Dose Melphalan for BSCTCompletedNCT01242267Phase 1/2Results posted
• Tandem Auto Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple MyelomaCompletedNCT01241708Phase 3Results posted
• Japanese Study of BMS-901608 (Elotuzumab) in Combination With Lenalidomide and Low Dose DexamethasoneCompletedNCT01241292Phase 1Results posted
• Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple MyelomaCompletedNCT01239797Phase 3Results posted
• Th1/Tc1 Immunotherapy Following Stem Cell Transplantation in Multiple MyelomaTerminatedNCT01239368Phase 1/2Results posted
• High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic-Cell Support for Patients With Poor-Risk MyelomaCompletedNCT01237951Phase 2Results posted
• Imaging in MGUS, SMM and MMCompletedNCT01237054Phase 2Results posted
• Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic CancerCompletedNCT01233921Not applicableResults posted
• Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell TransplantCompletedNCT01231412Phase 3Results posted
• A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple MyelomaCompletedNCT01217957Phase 1/2Results posted
• First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With VelcadeCompletedNCT01215344Phase 2Results posted
• Pomalidomide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT01212952Phase 1/2Results posted
• Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65Active, not recruitingNCT01208662Phase 3Results posted
• Zevalin for Patients With Incomplete Response to Chemo Prior to Autologous Stem Cell Transplant for Multiple MyelomaTerminatedNCT01207765Phase 2Results posted
• Efficacy and Safety Study of SyB L-0501 for Patients With Multiple MyelomaTerminatedNCT01179490Phase 2Results posted
• Pomalidomide in Gene Expression Profiling (GEP)-Defined High-risk Multiple MyelomaCompletedNCT01177735Phase 2Results posted

← Multiple Myeloma overview